Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.
Anti-relapse treatment
Corticosteroid
Sarcoidosis
Uveitis
Vogt-Koyanagi-Harada disease
Journal
Japanese journal of ophthalmology
ISSN: 1613-2246
Titre abrégé: Jpn J Ophthalmol
Pays: Japan
ID NLM: 0044652
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
30
05
2021
accepted:
24
11
2021
pubmed:
20
1
2022
medline:
3
3
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Non-infectious uveitis associated with Vogt-Koyanagi-Harada (VKH) disease or sarcoidosis is commonly treated with systemic corticosteroids (SCS). We assessed the use of SCS for non-infectious uveitis relapses in Japanese clinical practice. Multicenter, retrospective chart review (UMIN Clinical Trial Registry; UMIN000032390). One hundred fifty-seven patients (15- ≤ 75 years; 103 VKH disease, 54 sarcoidosis) given SCS to treat a relapse of non-infectious intermediate, posterior, or panuveitis accompanying VKH disease or sarcoidosis were studied (August 2011-December 2018). SCS dose and duration, concomitant medications, subsequent relapses, and steroid-related adverse drug reactions (ADRs) were analyzed for 12 months after target relapse treatment. Relationships between background factors and total SCS dose were analyzed (logistic regression). Mean (± SD) total SCS dose over 12 months after target relapse treatment was 3874 ± 2775 mg, and was higher in patients with immunosuppressants than in those without (4575 mg vs 3496 mg). Immunosuppressant use was the only factor significantly associated with higher total SCS dose (p = 0.0196). Mean duration of SCS treatment for relapse was 318.7 ± 89.3 days. Only 29.3% of patients were steroid-free after 12 months; the percentage was higher in patients without immunosuppressants (36.3% vs 16.4%). Subsequent relapse was experienced by 39.5% of patients, and 13.4% had a steroid-related ADR (mostly glaucoma or diabetes). In Japanese clinical practice, many patients with recurrent uveitis accompanying VKH disease or sarcoidosis received SCS for relapse for ≥ 300 days, suggesting that reducing corticosteroids is challenging in patients with difficulty suppressing inflammation.
Identifiants
pubmed: 35044561
doi: 10.1007/s10384-021-00897-7
pii: 10.1007/s10384-021-00897-7
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-141Informations de copyright
© 2022. Japanese Ophthalmological Society.
Références
Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther. 2014;3:17–36.
doi: 10.1007/s40123-014-0023-x
Valenzuela RA, Flores I, Urrutia B, Fuentes F, Sabat PE, Llanos C, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A minireview. Front Pharmacol. 2020;11:655.
doi: 10.3389/fphar.2020.00655
Zhao C, Zhang M. Immunosuppressive treatment of non-infectious uveitis: history and current choices. Chin Med Sci J. 2017;32:48–61.
doi: 10.24920/J1001-9242.2007.007
Baltmr A, Lightman S, Tomkins-Netzer O. Vogt-Koyanagi-Harada syndrome - current perspectives. Clin Ophthalmol. 2016;10:2345–61.
doi: 10.2147/OPTH.S94866
Kobak S. Sarcoidosis: a rheumatologist’s perspective. Ther Adv Musculoskelet Dis. 2015;7:196–205.
doi: 10.1177/1759720X15591310
Maruyama K. Current standardized therapeutic approach for uveitis in Japan. Immunol Med. 2019;42:124–34.
doi: 10.1080/25785826.2019.1678961
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
doi: 10.1016/S0002-9394(00)00659-0
Takase H, Acharya NR, Babu K, Bodaghi B, Khairallah M, McCluskey PJ, et al. Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis. Br J Ophthalmol. 2021;105:1515–9.
doi: 10.1136/bjophthalmol-2020-317354
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.
doi: 10.1186/1710-1492-9-30
Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952–7.
doi: 10.1136/annrheumdis-2015-208916
Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905–13.
doi: 10.1136/annrheumdis-2013-203249
Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975–94.
doi: 10.1016/j.rmed.2009.01.003
Ministry of Health, Welfare and Labour. Ethical guidelines for medical and health research involving human subjects. 2008. https://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/rinsyo/dl/shishin.pdf . Accessed 22 Apr 2021.
Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.
doi: 10.1016/S0002-9394(01)00925-4
Sugisaki K. Diagnostic guidelines and criteria for sarcoidosis—2006. Nihon Kokyuki Gakkai Zasshi. 2008;46:768–80 (in Japanese).
pubmed: 18939424
Japan Society of Sarcoidosis and Other Granulomatous Disorders. Diagnosis criteria and classification of disease severity. 2015. https://www.jssog.com/wp/wp-content/themes/jssog/images/system/guidance/1-2.pdf . Accessed 22 Apr 2021.
Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.
doi: 10.1016/j.ajo.2005.03.057
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.
doi: 10.1016/S0161-6420(85)34001-0
Trusko B, Thorne J, Jabs D, Belfort R, Dick A, Gangaputra S, et al. The Standardization of Uveitis Nomenclature (SUN) project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52:259–65 (S1-6).
doi: 10.3414/ME12-01-0063
American Academy of Ophthalmology. Practicing ophthalmologists curriculum 2014–2016. https://www.aao.org/assets/3a0a9dfd-e769-4e96-b49d-36c504fb518a/635222148920430000/core-2014-pdf . Accessed 4 Jan 2022.
Jamilloux Y, Kodjikian L, Broussolle C, Sève P. Sarcoidosis and uveitis. Autoimmun Rev. 2014;13:840–9.
doi: 10.1016/j.autrev.2014.04.001
O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;62:1–25.
doi: 10.1016/j.survophthal.2016.05.002
Japanese Society of Sarcoidosis and Other Granulomatous Disorders, Japanese Respiratory Society, Japanese College of Cardiology, Japanese Ophthalmological Society, MHLW Study Group of Diffuse Lung Disease. Opinion – 2003 about sarcoidosis treatment. Nihon Kokyuki Gakkai Zasshi. 2003;41:150–9 (in Japanese).
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–106.
doi: 10.1136/gutjnl-2019-318484
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf . Accessed 22 Apr 2021.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2020. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf . Accessed 22 Apr 2021.
Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6:e000536.
doi: 10.1136/rmdopen-2017-000536
Errera M-H, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2011;89:e357–66.
doi: 10.1111/j.1755-3768.2010.02055.x
Lai TYY, Chan RPS, Chan CKM, Lam DSC. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond). 2009;23:543–8.
doi: 10.1038/eye.2008.89
Makol A, Davis JM 3rd, Crowson CS, Therneau TM, Gabriel SE, Matteson EL. Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980–1994 versus 1995–2007. Arthritis Care Res (Hoboken). 2014;66:1482–8.
doi: 10.1002/acr.22365
Su B, Zhang Q, Lv J. Cryptococcal meningitis in adult patients with primary nephrotic syndrome. Clin Nephrol. 2018;90:390–5.
doi: 10.5414/CN109384
Gale S, Wilson JC, Chia J, Trinh H, Tuckwell K, Collinson N, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther. 2018;5:327–40.
doi: 10.1007/s40744-018-0112-8
Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13:206–14.
doi: 10.1016/j.autrev.2013.10.013
Nawata K, Nakamura J, Ikeda K, Furuta S, Nakajima H, Ohtori S, et al. Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids. Rheumatology. 2018;57:844–9.
doi: 10.1093/rheumatology/key009
Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina J-A, Moran M-A, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology. 2014;53:1470–6.
doi: 10.1093/rheumatology/keu148
Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–84.
doi: 10.1016/j.ophtha.2009.08.010
Palestine AG, Nussenblatt RB, Chan CC. Treatment of intraocular complications of sarcoidosis. Ann N Y Acad Sci. 1986;465:564–74.
doi: 10.1111/j.1749-6632.1986.tb18533.x
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–43.
doi: 10.1056/NEJMoa1509852
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–92.
doi: 10.1016/S0140-6736(16)31339-3
Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075–87.
doi: 10.1016/j.ophtha.2017.12.039